trending Market Intelligence /marketintelligence/en/news-insights/trending/__oEViabHSO_DJdOjJMwDA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Selecta Biosciences licenses Pompe disease therapy to Asklepios

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Selecta Biosciences licenses Pompe disease therapy to Asklepios

Watertown, Mass.-based Selecta Biosciences Inc. is licensing its immune tolerance platform, called ImmTOR, for the treatment of Pompe disease to Asklepios BioPharmaceutical Inc. in exchange for over $240 million in up-front and milestone payments.

Pompe disease is a rare, inherited disorder that affects ventilator, cardiac and skeletal muscles, causing motor neuron dysfunction. The disease affects between 5,000 and 10,000 people worldwide.

Asklepios will have the worldwide license to develop and commercialize ImmTOR for use in adeno-associated virus gene therapy for the treatment of the disease.

The companies previously announced their collaboration in August for jointly developing, manufacturing and commercializing therapeutics for AAV gene therapies for diseases with limited treatment options.

Research Triangle Park, N.C.-based Asklepios is a privately held gene therapy platform company that develops treatments for genetic disorders.